Elevation Oncology Inc. (NASDAQ: ELEV)
$0.5596
-0.0139 ( -3.52% ) 354.1K
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Market Data
Open
$0.5596
Previous close
$0.5735
Volume
354.1K
Market cap
$33.67M
Day range
$0.5500 - $0.5930
52 week range
$0.4401 - $5.8299
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 18, 2024 |
4 | Insider transactions | 1 | Nov 19, 2024 |
10-q | Quarterly Reports | 74 | Nov 06, 2024 |
8-k | 8K-related | 16 | Nov 06, 2024 |
8-k | 8K-related | 14 | Sep 20, 2024 |
4 | Insider transactions | 1 | Sep 18, 2024 |
4 | Insider transactions | 1 | Aug 19, 2024 |
10-q | Quarterly Reports | 75 | Aug 06, 2024 |
8-k | 8K-related | 16 | Aug 06, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |